# A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

> **NCT00502112** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 13 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** lintuzumab
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00502112
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502112, "A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00502112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*